BSD, AngioCare in MicroThermX Pact - Analyst Blog

Cancer treatment systems maker BSD Medical ( BSDM ) recently forged an exclusive deal with AngioCare BV for the distribution of its MicroThermX Microwave Ablation products in The Netherlands.

AngioCare is a leading specialty distributor in The Netherlands and has a successful history of bringing novel products/technologies to the interventional radiology market. The entity has association with a number of major medical devices makers and sells medical products to the same physicians and market aimed for MicroThermX.

AngioCare has already purchased the MicroThermX products (and associated antennas) and presented them to key opinion leaders. The entity has a dedicated sales force specialized in marketing products to the interventional radiology/oncology market, which will ensure that the benefits of MicroThermX reaches the interventional oncologists throughout The Netherlands.

BSD Medical launched the MicroThermX system in the U.S. in December 2010. The Utah-based company subsequently introduced its first MicroThermX system in Europe in January 2011.

The MicroThermX system is a transportable, cutting-edge proprietary product, which includes a microwave generator, single-use antennas and a temperature monitoring mechanism. It is capable of generating significant levels of power with one generator. Its usage helps approach larger and more uniform areas of ablation during a procedure.

The MicroThermX system utilizes BSD Medical's proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna. The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures.

BSD Medical provides hyperthermia and ablation therapy systems to treat cancer and benign diseases. It competes with established players like Boston Scientific ( BSX ) and Angiodynamics ( ANGO ) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.

ANGIODYNAMICS ( ANGO ): Free Stock Analysis Report

BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More